FDA recall, , Moderate risk
American Red Cross Apheresis Red Blood Cells, Leukocytes Reduced
Apheresis Red Blood Cells, Leukocytes Reduced were labeled as leukocytes reduced but were not tested to verify white blood cell count.
Recall ended Aug 3, 2026. Still check yours.
Summary by Recall Canary from the FDA notice
What happened
The FDA announced that American Red Cross Blood Services - Massachusetts Region began a recall of Apheresis Red Blood Cells, Leukocytes Reduced on April 30, 2025, because the products were labeled as leukocytes reduced but were not tested to verify white blood cell count. The recall was added to the FDA's Enforcement Report on August 3, 2026, and was distributed in New York.
What to do
We don't have product-specific instructions for this recall. FDA's general advice for medicine recalls:
- Check the FDA or company notice for instructions specific to this product.
- Ask your pharmacist or doctor whether your lot is affected and what to do.
Is yours affected?
Compare these details with yours, then check the recall notice to see which units are recalled.
Apheresis Red Blood Cells, Leukocytes Reduced
Recall details
- Company began the recall
- Sold in
- Company
- American Red Cross Blood Services - Massachusetts Region
- Hazard
- Quality testing problem
- Risk
Moderate risk
Taking it may cause short-term health problems, or ones that treatment can reverse. Serious harm is unlikely.
FDA Class II recall · How risk is rated
- Event ID
- 99393
- Recall number
- B-0166-2026
All recalls from American Red Cross Blood Services - Massachusetts Region
Timeline
FDA's Enforcement Report is its public list of recalls; FDA adds a recall when it posts it and publishes the list weekly.
Company began the recall
Added to FDA's Enforcement Report · Classified by FDA · Recall ended
In FDA's weekly enforcement report
Listed on Recall Canary
